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Background: Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an
agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal
antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for
continuation of cancer therapy, there are no effective precautionary treatments.
Case presentation: A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was
treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.
During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually
appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of
the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.
Conclusion: We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin
disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of
colorectal cancer therapy.
Keyword: Abound, Anti-EGFR antibody, Skin disorder, Colon cancerBackground
In recent years, remarkable progress has been made in
chemotherapy for colorectal cancer. In particular, the
treatment for advanced or metastatic colorectal cancer
has dramatically improved owing to the development of
FOLFOX and FOLFIRI therapies. Furthermore, the intro-
duction of targeted therapy has made the treatment more
effective and helpful for patients suffering from colorectal
cancer. However, as an example of peripheral neuropathy,
a serious major side effect of oxaliplatin (L-OHP), the
control of adverse events is difficult for the continuation
of cancer therapy. In addition, at the same time, the pre-
vention of skin disorder associated with anti-epidermal
growth factor receptor (EGFR) antibody therapy is import-
ant to continue the cancer therapy. However, at present,* Correspondence: kyoshida@gifu-u.ac.jp
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symptomatic.
Abound™ (ABBOTT JAPAN CO., LTD, Tokyo) consti-
tuted by a mixture of β-hydroxyl β-methylbutyrate, gluta-
mine, and arginine (HMB/Gln/Arg). Abound™ previously
showed activity for healing bed ulcers, increasing lean body
mass (LBM) among patients with cancer cachexia [1,2].
Therefore, our hypothesis considered whether Abound™ is
effective for cancer patients with skin disorder. We report
that Abound™ was effective for a non-resectable colorectal
cancer patient treated with an anti-EGFR antigen panitu-
mumab who had developed skin disorder.Case presentation
A 74-year-old male with sigmoid colon cancer and syn-
chronous lung metastasis (stage IV) underwent high an-
terior resection and D3 lymphadenectomy. The patient
received 16 courses of FOLFOX and bevacizumab (BV)tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Before and after images of AboundTM treatment: face. (a) Before AboundTM was administered (CTCAE version 4.0: Grade 2).
(b) After AboundTM was administered (CTCAE version 4.0: Grade 1). CTCAE, common terminology criteria for adverse events.
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disease progression, the patient was followed by BV and
FOLFIRI as second-line therapy. The patient’s perform-
ance status (PS) went down to PS 1 in accordance with
accumulation of the side effect of FOLFIRI therapy, but
disease control indicated progression of the disease.
Therefore, the patient was started on only panitumumab
therapy, an anti-EGFR antigen, in order to wild type the
Kras gene type.
An antibiotic agent, minocycline hydrochloride (mino-
cycline), and an external preparation, dexamethasone,Figure 2 Before and after images of Abound™ treatment: lower limbs
(b) After Abound™ was administered (CTCAE version 4.0: Grade 0). CTCAE,were administered form the start of the panitumumab
therapy for prophylaxis of the skin disorder.
During the second course of the anti-EGFR antibody
therapy, skin disorder appeared on the patient’s facial
surfaces and gradually on other parts. The symptomatic
treatment was continued; however, at the end of the
ninth course of the anti-EGFR antibody therapy, the skin
disorder was observed on both the lower limbs as well as
on the face remarkably. Thus, AboundTM containing
HMB/Gln/Arg was administered with two packs (48 g) a
day. The skin disorder on both the lower limbs. (a) Before Abound™ was administered (CTCAE version 4.0: Grade 2).
common terminology criteria for adverse events.
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Abound™ (Figures 1a,b and 2a,b).
Discussion
Molecules of the EGFR family compose signal transduc-
tion pathways and play a major role in intracellular reac-
tion processes [3-5]. New entities have been developed to
target the pathway because EGFR has been observed in
high frequency in non-small cell lung cancer (NSCLC)
and colorectal or pancreatic cancer. EGFR tyrosine kinase
inhibitors, including gefitinib and erlotinib, were launched
as chemotherapy agents for NSCLC. Recently, cetuximab
and panitumumab as EGFR monoclonal antigens have
been made available for the treatment of colorectal
cancer [6-9].
These agents are characteristically known to cause the
side effect of frequent skin disorder, and thus the control
of the skin disorder itself and its symptoms are very im-
portant for cancer therapy. From this point of view, skin
disorder with inhibitors of the EGFR system can be used
to continue the drug administration for cancer therapy,
which is most important simultaneous with symptom
control of the skin disorder [10]. In addition, with
regards to erlotinib, correlation between the severity of
skin disorder and the curative effect against cancer has
shown that when the severity of skin disorder is higher,
the curative effect is higher, and it has been suggested
that cetuximab and panitumumab may demonstrate the
same characteristics [11,12].
At present, minocycline hydrochloride (minocycline)
with steroidal agents are recognized as supportive treat-
ment for the prevention of skin disorder with anti-EGFR
antibody, utilized in various institutes, in accordance
with the results of the skin toxicity evaluation protocol
with panitumumab (STEPP) study [13].
In this case, we administered Abound™ containing
HMB/Gln/Arg, and observed improvement of the skin
disorder. HMB, a metabolite of leucine, is suggested to
promote collagen deposition with modification of muscle
protein degradation and to modulate inflammatory reac-
tion by inhibiting the activity of NF-κB. Arginine is a
semi-essential amino acid that can enhance immunity and
wound healing by potentiating the cellulation process of
fibroblasts. Glutamine is supposed to relate to the meta-
bolic response of external injury and sepsis and to en-
hance gut immunity by affecting lymphocytes and
intestinal epithelium cells, and has an effect on the im-
provement of gastrointestinal disorders for patients
receiving anti-cancer chemotherapy. Since AboundTM
is a dietary supplement, it is well tolerated, without
any reported side effects. Abound™ has been shown
to have efficacy on the nutritional management of
cancer and HIV cachexia patients, and HMB/Gln/Arg
supplementation can be important for those patients[2,14-16]. The HMB/Gln/Arg levels in advanced, meta-
static, or recurrent cancer patients are considered to be
low. Abound™, one pack of which contains 1,200 mg of
HMB, 7,000 mg of glutamine, and 7,000 mg of arginine,
can support balanced nutritional management, and in this
case report we suggest that Abound™ may promote wound
healing in skin disorder.
Conclusion
In the future, prospective studies of Abound™ in patients
treated with anti-EGFR antibody is necessary, but our
report indicates that Abound™ may have the potential to
support nutritional status and to improve skin disorder.
Thus, when larger studies can demonstrate the efficacy,
Abound™ could provide an effective option for the
management of side effects in colorectal cancer treatment.
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